Iambic Advances Pipeline, Cites Revenue and AI Growth
Iambic reported Q3 2026 revenue of $24M and $252M cash, plus progress on drug trials and AI partnerships, including new deals with Bayer and AbbVie.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed